This observation offers the potential to repurpose PD-1 as a site for targeted integration of therapeutic transgenes, capitalizing the kinetics of PD-1 expression after antigen encounter to restrict transgene expression to the tumor microenvironment while simultaneously disrupting PD-153,54. Here, PDCD1 is linked to neoplasm.